Marina Tschaika
About Marina Tschaika
Marina Tschaika is the Senior Director of Global Clinical Research Oncology at Bristol-Myers Squibb, with over 20 years of experience in global clinical development, particularly in oncology and immuno-oncology.
Company
Marina Tschaika currently holds the role of Senior Director of Global Clinical Research Oncology at Bristol-Myers Squibb, located in Lawrenceville, NJ, US. She has a history of working with both large pharmaceutical companies and smaller biotechnology firms, demonstrating a diverse and extensive background in the field.
Title
Marina Tschaika is the Senior Director of Global Clinical Research Oncology. In this capacity, she provides clinical oversight and guidance to study teams, ensuring data reliability and quality across clinical development programs. Her role involves significant strategic portfolio development and regulatory affairs.
Education and Expertise
Marina holds a Master's Degree in Pharmaceutical Medicine from the PME Institute for Education in Pharmaceutical Medicine GmbH, University Duisburg Essen, Germany. She also achieved a Master of Business Administration (M.B.A.) in Business Administration and Management from American InterContinental University Online, USA. She has over 20 years of experience in global clinical development, particularly focused on oncology and immuno-oncology, with expertise in managing clinical development programs for a variety of solid tumor types.
Background
Marina Tschaika has a rich professional background with roles in prestigious organizations. She was the Head of Clinical Development at Mologen AG from 2009 to 2012 and Senior Medical Director at Jerini AG from 2007 to 2009. At Johnson & Johnson, Division of Janssen-Cilag, she served as Global Project Manager Phase I Studies from 2005 to 2007. She founded and served as the CEO of PharmaEast Clinical Research from 2001 to 2005.
Achievements
Marina has significantly contributed to the development and execution of clinical studies for major immuno-oncology treatments such as nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor). She has developed essential study documents, provided clinical oversight, and ensured the quality and reliability of study data. Her extensive experience includes interactions with authorities, investigators, and thought leaders in the field.